Archive | Papers RSS feed for this section

To Transplant or Not To Transplant in Multiple Myeloma

March 1, 2017

0 Comments

Clinical Advances in Hematology & Oncology Authors: James R. Berenson, MD, Claudia Andreu-Vieyra, PhD, Sergio Giralt, MD May 2014, Volume 12, Issue 5 High-dose therapy in combination with autologous stem cell transplantation (ASCT) has become the standard of care for younger multiple myeloma patients. Is ASCT still the best treatment for these patients in the […]

Continue reading...

Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma

February 19, 2013

0 Comments

Br J Haematol. 2013 Feb;160(3):321-30. doi: 10.1111/bjh.12129. Epub 2012 Nov 15. Berenson JR, Yellin O, Bessudo A, Boccia RV, Noga SJ, Gravenor DS, Patel-Donnelly D, Siegel RS, Kewalramani T, Gorak EJ, Nassir Y, Swift RA, Mayo D. Abstract Bendamustine, active in multiple myeloma (MM), is a bifunctional mechlorethamine derivative with alkylating properties. Bortezomib, approved to […]

Continue reading...

CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma

November 19, 2012

0 Comments

Leuk Res. 2012 Nov;36(11):1422-7. doi: 10.1016/j.leukres.2012.07.018. Epub 2012 Aug 17. Sanchez E, Li M, Li J, Wang C, Chen H, Jones-Bolin S, Hunter K, Ruggeri B, Berenson JR. Abstract Preclinical and clinical studies have shown that proteasome inhibitors (PIs) have anti-MM activity in combination with dexamethasone or lenalidomide. However, no data exists on the anti-MM […]

Continue reading...

Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival

September 18, 2012

Comments Off on Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival

Br J Haematol. 2012 Sep;158(6):727-38. doi: 10.1111/j.1365-2141.2012.09241.x. Epub 2012 Jul 18. Sanchez E, Li M, Kitto A, Li J, Wang CS, Kirk DT, Yellin O, Nichols CM, Dreyer MP, Ahles CP, Robinson A, Madden E, Waterman GN, Swift RA, Bonavida B, Boccia R, Vescio RA, Crowley J, Chen H, Berenson JR. Abstract Although TNFRSF17 (also […]

Continue reading...

The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo

March 19, 2011

0 Comments

Leuk Res. 2011 Mar;35(3):373-9. doi: 10.1016/j.leukres.2010.06.026. Epub 2010 Jul 21. Sanchez E, Shen J, Steinberg J, Li M, Wang C, Bonavida B, Chen H, Li ZW, Berenson JR. Abstract Panobinostat (LBH589) is a potent histone deacetylase inhibitor (HDACi) that has shown anti-tumor activity in preclinical studies in both solid and hematological malignancies. We evaluated the […]

Continue reading...